> Just a few weeks after announcing that a cash crisis had forced Plymouth Meeting, PA-based Genaera to eliminate most of its remaining staff, the developer announced that it would shut down and liquidate. Genaera release
> Amylin and Eli Lilly have struck a deal to co-develop a new pen device to deliver the Type 2 diabetes drug exenatide. Lilly will cover 60 percent of the $216 million cost with Amylin footing the rest of the bill. Report
> Shares of Ipsen jumped on the news that the FDA had approved its therapy to reduce wrinkles. Release l Story
> Can-Fite BioPharma announced that a Phase IIb trial of the rheumatoid arthritis therapy CF101 failed to hit its primary endpoint. Researchers found no statistical difference between the group taking CF101 and the group taking a placebo. Report
>Spain's Almirall says its reached agreement with Forest on a clinical and regulatory strategy for the lung drug aclidinium bromide. Story
> The FDA charged seven internal "teams" with influenza-management jobs. Officials are talking to the House Energy and Commerce Committee about the outbreak. And HHS Secretary Kathleen Sebelius (photo) is set to participate in an all-flu-star webcast later today; submit your questions now. Report
> Is pharma's future not in pharma? That's the contention of Pricewaterhouse Coopers, the consulting firm that periodically offers a state-of-the-industry address. Report
> Good news for judges looking to clear their dockets, not so good news for pharma: Lawsuits long stalled by the debate over legal preemption are coming out of the deep freeze. Report
> Novartis will use data on a new vaccine adjuvant as it moves to design a new jab specifically for swine flu. Report
> Using a cocktail of proteins drawn from A and B influenza strains, researchers are testing a universal flu vaccine that could provide broad protection against a variety of seasonal flu strains and may help guard against pandemics. Vaccine report
And Finally... Biotech and pharmaceutical executives-including Vertex Pharmaceuticals chief executive Joshua Boger and a chief science officer at Pfizer--as well as scientists and science journalists--have been "impersonated" on Facebook recently, with pranksters (or worse) creating fake online identities. Report